BeOne Medicines (NASDAQ:ONC) and Veru (NASDAQ:VERU) Financial Comparison

BeOne Medicines (NASDAQ:ONC – Get Free Report) and Veru (NASDAQ:VERU – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Profitability

This table compares BeOne Medicines and Veru’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BeOne Medicines 13.86% 19.04% 10.70%
Veru N/A -47.58% -35.83%

Volatility & Risk

BeOne Medicines has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Veru has a beta of -1.2, meaning that its share price is 220% less volatile than the S&P 500.

Valuation and Earnings

This table compares BeOne Medicines and Veru”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BeOne Medicines $6.61 billion 6.71 $286.93 million $7.87 51.28
Veru $16.89 million 2.33 -$22.73 million ($0.69) -3.35

BeOne Medicines has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for BeOne Medicines and Veru, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BeOne Medicines 0 1 16 1 3.00
Veru 1 0 3 0 2.50

BeOne Medicines currently has a consensus price target of $440.56, suggesting a potential upside of 9.16%. Veru has a consensus price target of $24.50, suggesting a potential upside of 960.61%. Given Veru’s higher possible upside, analysts plainly believe Veru is more favorable than BeOne Medicines.

Insider and Institutional Ownership

48.5% of BeOne Medicines shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by insiders. Comparatively, 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

BeOne Medicines beats Veru on 13 of the 15 factors compared between the two stocks.

About BeOne Medicines

(Get Free Report)

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia. Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.

About Veru

(Get Free Report)

Veru Inc. is a biopharmaceutical company focused on developing medicines for metabolic diseases and cancer. Its research programs include enobosarm, which is being studied to help preserve muscle during weight loss associated with GLP-1 medicines, as well as candidates investigated for breast and prostate cancer. The company has also developed sabizabulin, an investigational drug studied for cancer treatment. These medicines remain development-stage products; Veru’s clinical programs and priorities may change as research progresses.

Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.